Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Akebia Therapeutics ( (AKBA) ).
On January 12, 2026, Akebia Therapeutics announced corporate updates and a 2026 pipeline outlook that underscore its bid to make Vafseo a standard-of-care treatment for anemia due to chronic kidney disease in dialysis while building a broader rare kidney disease franchise. In 2025, the company secured broad prescribing access to roughly 275,000 dialysis patients, advanced large post-marketing trials such as the VOICE and VOCAL studies to compare Vafseo with erythropoietin stimulating agents, and increased Vafseo prescriber numbers and demand despite a Q4 2025 revenue impact from inventory adjustments tied to a new observed dosing protocol at U.S. Renal Care. Akebia expects Vafseo revenue growth to resume in the first quarter of 2026 as access, adherence and compliance improve, and is simultaneously progressing a mid-stage rare kidney disease pipeline, including dosing the first patient in a Phase 2 praliciguat trial for focal segmental glomerulosclerosis in December 2025, planning a Phase 2 basket study of AKB-097 in multiple complement-mediated kidney diseases from the second half of 2026 with initial data in 2027, and moving AKB-9090 into Phase 1 for acute kidney injury associated with cardiac surgery, positioning its revenue-generating products to fund pipeline expansion and potential long-term growth.
The most recent analyst rating on (AKBA) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Akebia Therapeutics stock, see the AKBA Stock Forecast page.
Spark’s Take on AKBA Stock
According to Spark, TipRanks’ AI Analyst, AKBA is a Neutral.
The score is held back primarily by balance-sheet leverage and weak technical trend signals. Offsetting factors include improving TTM operating/FCF performance and an earnings call that highlighted strong Vafseo launch traction and revenue growth, though execution challenges and mixed corporate-event signals keep risk elevated.
To see Spark’s full report on AKBA stock, click here.
More about Akebia Therapeutics
Akebia Therapeutics, Inc., founded in 2007 and headquartered in Cambridge, Massachusetts, is a fully integrated biopharmaceutical company focused on improving the lives of people with kidney disease. Its lead product, Vafseo (vadadustat) tablets, is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor approved in 37 countries for treating anemia due to chronic kidney disease in adults on dialysis, and the company is expanding a nephrology-focused pipeline that includes mid-stage and early-stage candidates for rare kidney diseases and acute kidney injury.
Average Trading Volume: 4,141,279
Technical Sentiment Signal: Sell
Current Market Cap: $395.4M
Find detailed analytics on AKBA stock on TipRanks’ Stock Analysis page.